# Constipation

Evaluate constipation by first excluding obstruction, cancer-risk features, fecal impaction, medication effects, and systemic disease; then distinguish defecatory disorder from slow-transit and normal-transit phenotypes before escalating beyond empiric laxatives. Anorectal testing directs biofeedback and prevents inappropriate transit testing or surgery.

**Clinical question:** How should physicians evaluate and treat constipation while identifying defecatory disorders, secondary causes, and patients requiring structural evaluation?

Updated: 2026-09-16T00:50:48.272786+00:00

## What matters in practice
- Perform a medication review and digital rectal examination early; the examination can detect fecal impaction and identify findings suggestive of dyssynergia. [4][22]
- Reserve colonoscopy and other structural evaluation for alarm features, age-appropriate colorectal cancer screening needs, or a concerning clinical trajectory; routine laboratory testing and endoscopy have limited value without alarm features. [22]
- In constipation unresponsive to over-the-counter agents, evaluate suspected defecatory disorder with anorectal manometry plus rectal balloon expulsion testing; balloon expulsion testing should not establish the diagnosis alone. [12][22][23]
- For adult chronic idiopathic constipation, polyethylene glycol, secretagogues, and prokinetic agents are pharmacologic options; treatment guidance for this population does not apply to opioid-induced constipation, malignancy, pregnancy, children, or anorectal evacuation disorders. [15]
- When conventional measures fail in opioid-induced constipation, consider a peripherally acting mu-opioid receptor antagonist such as methylnaltrexone or naloxegol. [19]

## Identify patients who need urgent or structural evaluation

Separate impaction, possible organic disease, and secondary constipation before labeling symptoms idiopathic.

Escalate evaluation beyond empiric constipation management when the history identifies new or progressively worsening constipation, onset after age 50 years, hematochezia, weight loss, fever, anorexia, nausea or vomiting, or a family history of inflammatory bowel disease or colorectal cancer. These features shift the next step toward assessment for organic disease rather than physiologic testing alone. [22]

Perform a focused medication review, including opioid exposure, and a digital rectal examination. Rectal examination can identify fecal impaction, assess sphincter pressure, and elicit findings compatible with dyssynergic evacuation; medication-induced, systemic disease-associated, and organic disease-associated constipation are major secondary branches. [18][22][24]

Do not use constipation alone as a colorectal cancer discriminator: reported diagnostic sensitivity is 0.00 to 0.51 and specificity 0.53 to 0.90 across primary-care studies. Use the broader alarm-feature and screening context to decide on lower endoscopy. [5]
- Document stool frequency and form, straining, incomplete evacuation, anorectal blockage sensation, and manual maneuvers; these symptom domains characterize chronic constipation under Rome IV-based assessment. [18]
- Use a stool diary as an initial diagnostic tool when symptom frequency, stool form, or response to therapy is unclear. [22]
- Do not routinely order broad blood testing or endoscopy in patients without alarm features solely because they report constipation. [22]

*Clinical findings that redirect initial constipation evaluation. [22][18]*

| Finding | Interpretation | Immediate next action |
| --- | --- | --- |
| New or worsening constipation; onset after age 50 years; bleeding, weight loss, fever, anorexia, nausea/vomiting; family history of IBD or colorectal cancer [22] | Organic disease must be considered. [22] | Pursue structural and cause-directed evaluation rather than treating as uncomplicated primary constipation. [22] |
| Palpable rectal stool on digital rectal examination [22] | Fecal impaction is present or likely. [22] | Address impaction before interpreting failure of maintenance therapy or ordering physiology tests. [22] |
| Abnormal sphincter tone or impaired simulated evacuation on digital rectal examination [22] | Raises suspicion for dyssynergic defecation. [22] | If symptoms persist despite over-the-counter therapy, obtain anorectal manometry with balloon expulsion testing. [12][23] |
| Constipation starts or worsens with opioid initiation, change, or dose escalation [10] | Opioid-induced constipation is likely. [10] | Use an opioid-induced constipation treatment pathway rather than chronic idiopathic constipation guidance. [15][19] |

## Test refractory constipation in the sequence that identifies evacuation disorders first

Anorectal dysfunction can coexist with delayed transit and should be sought before assigning isolated slow-transit constipation.

For chronic constipation that does not respond to over-the-counter agents, obtain anorectal manometry and a rectal balloon expulsion test when a defecatory disorder is suspected. These are recommended initial tests for defecatory disorders; manometry measures anal sphincter function, rectal sensation and compliance, reflexes, and pressure changes during simulated evacuation. [12][23]

Interpret anorectal manometry in conjunction with balloon expulsion and the clinical examination. A negative rectoanal pressure gradient during evacuation occurs in many healthy individuals, so this manometric finding alone is not diagnostic. Similarly, balloon expulsion can confirm impaired evacuation but should not be used alone to diagnose dyssynergia. [12][22][23]

Use defecography or MR defecography when manometry and clinical findings disagree or when structural evacuation pathology is suspected, including clinically important rectocele or rectal prolapse. Relevant defecographic findings include abnormal perineal descent and abnormal anorectal-angle widening during defecation. [12][22]
- Use radiopaque-marker testing, wireless motility capsule testing, scintigraphy, or colonic manometry to evaluate colonic transit when the clinical question is slow-transit versus normal-transit constipation. [6]
- Recognize overlap: chronic constipation may reflect slow transit, defecatory disorder, normal transit, irritable bowel syndrome, or more than one mechanism. [6][24]
- Use a pathophysiologic diagnosis to direct treatment; anorectal manometry identifies patients likely to benefit from biofeedback therapy. [22]

### What each test changes

An abnormal balloon expulsion test plus supportive anorectal findings directs management toward pelvic-floor biofeedback rather than repeated escalation of laxatives alone. In contrast, impaired colonic transit testing supports a slow-transit phenotype after evacuation disorder has been considered. [22][24]
- Suspected rectal structural abnormality or discordant physiology testing: obtain defecography or MR defecography. [12][22]
- Persistent symptoms after over-the-counter treatment with suspected evacuation disorder: order anorectal manometry and balloon expulsion testing together. [12][23]

*Testing pathway for refractory constipation. [6][12][22][23]*

| Test | Best use | Key limitation | Result-directed action |
| --- | --- | --- | --- |
| Digital rectal examination [22] | Early assessment for impaction, sphincter pressure, and dyssynergic features. [22] | Does not replace formal anorectal testing when symptoms persist. [22] | Treat impaction; refer for anorectal testing when findings suggest impaired evacuation. [22] |
| Anorectal manometry [23] | Characterizes anorectal sensorimotor function and simulated evacuation. [23] | Evacuation pressures overlap with healthy individuals. [12][23] | Combine with balloon expulsion and clinical findings to diagnose defecatory disorder and guide biofeedback. [22][23] |
| Rectal balloon expulsion test [22] | Confirms impaired rectal evacuation. [22] | Should not be used as the sole diagnostic test. [22] | An abnormal result supports further integrated anorectal interpretation. [22][23] |
| Defecography or MR defecography [12][22] | Suspected rectocele, rectal prolapse, or discordant clinical and manometric findings. [12][22] | Not the routine first physiologic test. [12] | Define anatomic evacuation abnormalities that may change procedural planning. [12][22] |
| Colonic transit study [6] | Distinguishes delayed from normal colonic transit. [6] | Methods are not fully standardized. [22] | Supports slow-transit classification after considering evacuation disorder. [6][22] |

## Escalate pharmacotherapy by response while excluding an evacuation disorder

Apply chronic idiopathic constipation pharmacotherapy guidance only after secondary causes and relevant structural concerns are addressed.

For otherwise healthy adults with chronic idiopathic constipation, nonpharmacologic management may include increased fluid intake, dietary fiber, exercise, and behavioral change. Pharmacologic options include over-the-counter polyethylene glycol and prescription secretagogues or prokinetic agents. [15]

When over-the-counter treatment does not provide adequate relief, do not simply classify the patient as laxative-refractory. Reassess for a defecatory disorder with anorectal manometry and balloon expulsion testing, because anorectal testing identifies patients who may benefit from biofeedback rather than further drug escalation. [1][12][22][23]

Do not apply the adult chronic idiopathic constipation medication guideline to pediatric patients, pregnancy, opioid-induced constipation, malignancy-associated constipation, or anorectal evacuation disorders. These conditions require separate cause-specific management decisions. [15]
- Use polyethylene glycol as an osmotic laxative option for chronic idiopathic constipation. [15]
- Consider secretagogues or prokinetic agents when over-the-counter therapy is insufficient and an evacuation disorder is not the primary untreated mechanism. [15][22]
- Avoid routine fecal microbiota transplantation for constipation; current guidelines do not endorse it for routine clinical use. [16]

*Mechanism-based escalation for chronic constipation. [6][15][22]*

| Predominant pattern | Evidence-supported discriminator | Management implication |
| --- | --- | --- |
| Defecatory disorder [6] | Abnormal integrated anorectal assessment, including manometry and balloon expulsion testing. [22][23] | Use biofeedback-directed management rather than relying on laxative escalation alone. [22] |
| Slow-transit constipation [6] | Delayed transit on radiopaque markers, wireless motility capsule, scintigraphy, or colonic manometry. [6] | Use the transit phenotype to guide individualized medical management and avoid assuming an evacuation disorder is absent without appropriate assessment. [6][22] |
| Chronic idiopathic constipation without identified evacuation disorder [15] | Persistent symptoms after nonpharmacologic measures and over-the-counter therapy. [15] | Use polyethylene glycol, then consider secretagogues or prokinetic agents as clinically appropriate. [15] |

## Treat opioid-induced constipation as a distinct mechanism

Opioid exposure changes both the likely mechanism and the escalation pathway.

Diagnose opioid-induced constipation when constipation is new or worsens after opioid initiation, a change in opioid therapy, or opioid dose escalation. Opioid activation of enteric mu receptors reduces bowel tone and contractility, prolongs transit, and increases anal sphincter tone, impairing rectal evacuation. [10][19]

Begin with fluid intake, physical activity, and conventional laxative treatment. Fiber may worsen abdominal pain in opioid-induced constipation because it increases stool bulk without correcting impaired peristalsis; if conventional measures are inadequate, osmotic agents can be added. [19]

For persistent opioid-induced constipation despite conventional treatment, consider a peripherally acting mu-opioid receptor antagonist, including methylnaltrexone or naloxegol. This escalation is distinct from chronic idiopathic constipation pharmacotherapy guidance, which excludes opioid-induced constipation. [15][19]
- Anticipate opioid-induced constipation frequently: it has been reported in 40% of patients receiving opioids for nonmalignant pain and 90% of those receiving opioids for cancer pain. [19]
- Do not infer that a patient with opioid exposure has only medication-related constipation when alarm features, impaction, or a concerning examination is present; evaluate those findings independently. [22]

*Practical opioid-induced constipation escalation. [19][10]*

| Clinical stage | Action | Escalation trigger |
| --- | --- | --- |
| Constipation begins or worsens with opioid therapy [10] | Confirm temporal association; assess for impaction and alarm features. [10][22] | Organic-disease features or impaction require parallel evaluation and treatment. [22] |
| Initial management [19] | Increase fluids and physical activity; use a stool softener plus stimulant laxative in common practice, and add an osmotic agent if needed. [19] | Inadequate response to conventional measures. [19] |
| Laxative-refractory opioid-induced constipation [19] | Consider methylnaltrexone or naloxegol. [19] | Reassess the diagnosis and evaluate other causes if symptoms remain uncontrolled. [22] |

## Avoid tests and interpretations that do not change management

Testing should resolve a structural, evacuation, or transit question.

Avoid routine abdominal radiography to diagnose constipation from stool burden alone; diagnostic utility is limited, and an examination-centered approach better identifies impaction and anorectal dysfunction. [3][22]

Avoid interpreting one abnormal anorectal metric in isolation. High-resolution manometry pressure patterns during simulated evacuation overlap with healthy physiology, and the balloon expulsion test is confirmatory rather than independently diagnostic. [12][22][23]

Do not pursue surgery as a routine treatment for chronic constipation. Management is primarily dietary and lifestyle intervention, pharmacologic therapy, and physiologic phenotype-directed treatment; surgery is rarely used. [6]
- Do not use fecal microbiota transplantation routinely for constipation. [16]
- Do not use constipation symptoms alone to rule in or rule out colorectal cancer. [5]
- Do not treat all refractory symptoms as slow transit before assessing anorectal evacuation. [12][22]

*High-yield interpretation safeguards. [12][22][23]*

| Potential error | Why it misleads | Corrective action |
| --- | --- | --- |
| Diagnosing dyssynergia from manometry alone [12][23] | A negative rectoanal gradient during evacuation can occur in healthy people. [12] | Integrate digital rectal examination, balloon expulsion testing, and anorectal manometry. [22][23] |
| Diagnosing dyssynergia from balloon expulsion alone [22] | Balloon expulsion confirms impaired evacuation but is insufficient as a standalone diagnosis. [22] | Obtain anorectal manometry and reconcile results with the clinical examination. [22][23] |
| Using routine blood tests or endoscopy without alarm features [22] | Evidence for routine use in uncomplicated constipation is limited. [22] | Target testing to alarm features, cancer screening needs, and suspected secondary disease. [22] |

## References
1. Constipation: Advances in Diagnosis and Treatment - JAMA Network — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2481010
2. Effects of Electroacupuncture for Opioid-Induced ... — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2801734
3. Diagnostic Value of Abdominal Radiography in ... — jamanetwork.com — https://jamanetwork.com/journals/jamapediatrics/fullarticle/486071
4. Constipation - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/154
5. Value of symptoms and additional diagnostic tests for colorectal cancer in primary care: systematic review and meta-analysis — www.bmj.com — https://www.bmj.com/content/340/bmj.c1269
6. Chronic constipation | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/nrdp201795.pdf
7. Acupuncture for Chronic Severe Functional Constipation — annals.org — https://annals.org/aim/article/2552074/acupuncture-chronic-severe-functional-constipation-randomized-trial
8. Constipation | Annals of Internal Medicine - ACP Journals — annals.org — https://annals.org/aim/article/2218050/constipation
9. A Systematic Review and Network Meta-analysis | Nutrition ... — academic.oup.com — https://academic.oup.com/nutritionreviews/article/83/6/1006/7796597
10. a post hoc subgroup analysis of patients with lung cancer — academic.oup.com — https://academic.oup.com/jjco/article/51/3/444/5959800
11. Opioid-Induced Constipation and Bowel Dysfunction — academic.oup.com — https://academic.oup.com/painmedicine/article/18/10/1837/2649200
12. High-resolution Anorectal Manometry for Identifying Defecatory Disorders and Rectal Structural Abnormalities in Women - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1542356516308667
13. Pathophysiology of chronic childhood constipation: Functional and morphological evaluation by anorectal manometry and endosonography and colonic transit study - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0022346812007336
14. Opioid-Induced Constipation and Acupuncture: A Case Discussion - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0885392421001573
15. Pharmacological Management of Chronic Idiopathic Constipation — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10542656
16. Gut microbiota and constipation: from causal evidence to therapeutic strategies—a state-of-the-art narrative review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13429471
17. Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11303673
18. Evidence-Based Clinical Guidelines for Chronic Constipation 2023 — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC11825134
19. Chronic constipation: Update on management — www.ccjm.org — https://www.ccjm.org/content/84/5/397
20. Irritable Bowel Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK534810
21. Management of Functional Constipation in Children with Lower ... — www.auajournals.org — https://www.auajournals.org/doi/abs/10.1016/j.juro.2013.01.001
22. What is necessary to Diagnose Constipation? - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/3063397
23. A Review of the Indications, Methods, and Clinical Utility of Anorectal Manometry and the Rectal Balloon Expulsion Test - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9418387
24. Clinical utility of colonic and anorectal manometry in chronic constipation - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/20679903

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.